Efficacy and Safety of a Quadruple Combination Combivir + Abacavir + Efavirenz Regimen in Antiretroviral Treatment–Naive HIV-1–Infected Adults: La Francilienne

Truchis, Pierre de; Force, Gilles; Welker, Yves; Mechali, D.; Pulik, M; Chemlal, K; Rouveix, É.; Devidas, Alain; Praindhui, Danielle; Mamet, Jean-Philippe

doi:10.1097/00126334-200210010-00008

Cited by 9 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 In previous pilot studies, quadruple therapy with Combivir + abacavir + efavirenz was able to provide a rapid reduction of HIV replication, with a high proportion of patients reaching plasma HIV-1 RNA below the limits of detection at 48 weeks. 3,4 Following this initiation phase, a simplification phase could be considered to reduce pill burden, maintain a high level of adherence with a persistent long-term antiviral efficacy, and have an absence of treatment-limiting adverse events.…”

mentioning

confidence: 99%

Letter to the Editor: Long-Term Control of Viral Residual Replication Under Maintenance Therapy with Trizivir After a Quadruple Induction Regimen in HIV-1-Infected Adults (Suburbs Trial)

Truchis

Mathez

Force

et al. 2007

HIV Clinical Trials

View full text Add to dashboard Cite

mentioning

confidence: 99%

Letter to the Editor: Long-Term Control of Viral Residual Replication Under Maintenance Therapy with Trizivir After a Quadruple Induction Regimen in HIV-1-Infected Adults (Suburbs Trial)

Truchis

Mathez

Force

et al. 2007

HIV Clinical Trials

View full text Add to dashboard Cite

“…Although 48 week results from CNAA 3014 show a similar response to abacavir and indinavir for adults with VLs of >5 log copies/mL at baseline [28], adult treatment guidelines no longer recommend triple NRTIs for first‐line therapy. On‐going studies in adults are evaluating a strategy in which patients initiate therapy with ABC/AZT/3TC plus a fourth agent and then discontinue the fourth agent after a period of time (>6 months) and after the individual has a VL of <50 copies/mL (simplification) [29]. Triple NRTI regimens may also be of value if children are on antituberculosis treatment too.…”

Section: Which Art Regimen To Startmentioning

confidence: 99%

PENTA guidelines for the use of antiretroviral therapy, 2004

Sharland¹,

Blanche²,

Castelli³

et al. 2004

HIV Medicine

114

View full text Add to dashboard Cite

There have been few major advances in paediatric HIV management over the last 2 years. Decisions about starting antiretroviral therapy can now be based on a recent large meta-analysis of the predictive value of CD4 and HIV RNA viral load (VL) in nearly 4000 untreated children, which is discussed in these updated guidelines. Risk estimates for progression to AIDS and death using surrogate markers can now be broken down by age, allowing more accurate discussion with families. In addition, there is increasing recognition of the problems of long-term adherence, drug resistance and cumulative toxicity in adults and children. The controversy over whether to treat asymptomatic infants continues. For older children more data on the efficacy of ritonavir boosted protease inhibitor (PI) regimens suggests that these may be the PI option of first choice. There is still no adult or paediatric trial evidence on which to base decisions about whether to start with PI-or non-nucleoside reverse transcriptase inhbitor (NNRTI)-based regimens, but the PENPACT 1 trial, which is addressing this question, is ongoing. There are increasing moves to provide simpler antiretroviral therapy (ART) regimens, including once daily dosing, but these lag behind adult regimens because of the paucity of pharmacokinetic data. Resistance assays should now be performed in all HIV-infected infants exposed to ART in pregnancy. Therapeutic drug monitoring may be very important in children because of high between-and within-child variability in drug absorption and metabolism. A trial to evaluate this should start shortly in Europe (PENTA 14 trial). The value of resistance tests for choice of second-line and subsequent choices of ART regimens remain unproven (the PERA trial will report late in 2004), but resistance assays are increasingly being used. The issue of when to switch therapy also remains unanswered and is being addressed within the PENPACT 1 trial. Regular formal assessment of adherence is now the standard of care, and routine monitoring in the clinic for lipodystrophy syndrome (LDS) and other ART toxicities is increasingly important. These guidelines will be updated again in 2006.

show abstract

Current Awareness: Pharmacoepidemiology and Drug Safety

2003

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Efficacy and Safety of a Quadruple Combination Combivir + Abacavir + Efavirenz Regimen in Antiretroviral Treatment–Naive HIV-1–Infected Adults: La Francilienne

Cited by 9 publications

References 13 publications

Letter to the Editor: Long-Term Control of Viral Residual Replication Under Maintenance Therapy with Trizivir After a Quadruple Induction Regimen in HIV-1-Infected Adults (Suburbs Trial)

Letter to the Editor: Long-Term Control of Viral Residual Replication Under Maintenance Therapy with Trizivir After a Quadruple Induction Regimen in HIV-1-Infected Adults (Suburbs Trial)

PENTA guidelines for the use of antiretroviral therapy, 2004

Current Awareness: Pharmacoepidemiology and Drug Safety

Contact Info

Product

Resources

About